Management Of Malignant Pleural Effusion With Indwelling Pleural Catheter Versus Silver Nitrate Pleurodesis
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Assiut University
- Enrollment
- 50
- Primary Endpoint
- Success rate of silver nitrate pleurodesis
Study Overview
Brief Summary
The primary goal of this study is to compare well-defined pleural effusion management success outcomes in patients with malignant or paramalignant pleural effusions who were treated with Indwelling pleural catheter insertion compared with those treated with siver nitrate pleurodesis. It is also to demonstrate the effectiveness of silver nitrate pleurodesis. It is also important to evaluate frequent adverse events of silver nitrate pleurodesis in patients with malignant pleural effusion
Detailed Description
Dyspnea is present in 50% of patients with malignant pleural effusion and quality of life is significantly impaired.
Chemical pleurodesis using various sclerosing agents is accepted as a palliative therapy for patients with recurrent, symptomatic, and malignant pleural effusions.
Silver nitrate solution (SNS) is a valid sclerosing agent that induce a caustic injury to the mesothelium that results in an effective pleurodesis.
However, various clinical parameters and biochemical factors affect the success of pleurodesis in symptomatic patients with MPE: symptoms and performance status of the patient, daily fluid drainage, primary tumour, and mainly lung reexpansion following pleural fluid evacuation.
The pleural injectate consists of 50 mL 0.5% SNS with 10mL of lidocaine (25mg/5mL).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 30 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Unilateral symptomatic recurrent malignant pleural effusion patients who fulfill the criteria for pleurodesis (i.e. positive pleural biopsy or cytology for malignancy, a Karnofsky index score of more than 60 and life expectancy of more than one year).
- •Rapidly accumulated undiagnosed pleural effusion .
- •Age : 30-75 years old.
Exclusion Criteria
- •Transudative pleural effusion.
- •Exudative pleural effusion due to causes other than malignancy ( i.e. parapnuemonic , post-tuberculous pleural effusion )
- •Presence of hemorrhagic diathesis ( prothrombin time <50% and platelet count <80,000/mm 3 )
- •Active pleural or systemic infection.
- •Neoplastic infiltration of the skin at the site of pleural catheter insertion.
- •Malignant pleural effusion with trapped lung or loculated pleural effusion.
- •Previous lobectomy or pneumonectomy on the affected side.
- •Karnofsky index score> 50.
Arms & Interventions
Silver Nitrate Pleurodesis
Patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%
Intervention: Silver Nitrate (Drug)
Indwelling Pleural Catheter
Catheters will be inserted in an outpatient setting under local anaesthesia.The typical drainage schedule is every other day using disposable plastic bottles (550 mL to 1 L)
Intervention: Indwelling Pleural Catheter (Device)
Outcomes
Primary Outcomes
Success rate of silver nitrate pleurodesis
Time Frame: One month
Pleural fluid re-accumulation will be evaluated by chest x-ray and chest ultrasound.
Secondary Outcomes
- Chest pain: VAS(One week)
- Dyspnea(One week)
Investigators
Khaled Essmat Hussien
Principal Investigator
Assiut University